Triprilimab(JS001)

DRUG2 trials

Sponsors

Fujian Cancer Hospital, Sun Yat-sen University

Conditions

ChemotherapyImmunotherapyMetastasisNasopharyngeal CarcinomaSurvival

Phase 2

Triprilimab(JS001) and Chemotherapy Combined With Local Treatment for Multiple Metastatic NPC

Fujian Cancer HospitalNasopharyngeal Carcinoma

Start: 2020-06-15End: 2023-06-15Target: 39Updated: 2020-06-09

An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC

Not yet recruitingNCT04890522

Sun Yat-sen UniversityChemotherapy, Immunotherapy, Metastasis +2

Start: 2021-07-01End: 2028-12-31Target: 622Updated: 2021-05-18